Talphera (NASDAQ:TLPH – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Talphera to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent ratings for Talphera and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Talphera | 1 | 1 | 2 | 0 | 2.25 |
| Talphera Competitors | 7845 | 13797 | 25812 | 1039 | 2.41 |
Talphera currently has a consensus price target of $3.00, indicating a potential upside of 231.13%. As a group, “Pharmaceuticals” companies have a potential upside of 23.69%. Given Talphera’s higher probable upside, research analysts clearly believe Talphera is more favorable than its competitors.
Insider and Institutional Ownership
37.7% of Talphera shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Talphera has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Talphera’s competitors have a beta of -0.04, meaning that their average share price is 104% less volatile than the S&P 500.
Profitability
This table compares Talphera and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Talphera | N/A | -96.70% | -53.18% |
| Talphera Competitors | -2,398.26% | -203.62% | -15.08% |
Earnings and Valuation
This table compares Talphera and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Talphera | $30,000.00 | -$14.29 million | -3.36 |
| Talphera Competitors | $18.55 billion | $3.23 billion | 562.78 |
Talphera’s competitors have higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Talphera competitors beat Talphera on 8 of the 13 factors compared.
Talphera Company Profile
Talphera, Inc., formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing treatments for acute pain and critical care. The company’s portfolio includes DSUVIA, a sublingual formulation of sufentanil for the management of acute pain in adults in medically supervised settings. Talphera is also developing Niyad, a nafamostat-based anticoagulant intended for use in extracorporeal circuits during continuous renal replacement therapy. The company’s work in this area is aimed at addressing treatment needs in critical care settings.
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
